A statement released earlier today by Goldman Sachs Group Inc. about Bayer (ETR:BAYN) bumps the target price to 129.00EUR
- Updated: September 21, 2016
Goldman Sachs Group Inc. bumped up the target of Bayer (ETR:BAYN) to 129.00EUR stating a potential upside of 0.41%.
On 09/20/2016, S&P Capital IQ released a statement on Bayer (ETR:BAYN) bumped up the target price from 0.00EUR to 120.00EUR that suggested an upside of 0.30%.
Boasting a price of 91.46EUR, Bayer (ETR:BAYN) traded 0.00% even on the day. With the last close up -4.07% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Bayer has recorded a 50-day average of 0.04EUR and a two hundred day average of 0.03EUR. Volume of trade was down over the average, with 0 shares of BAYN changing hands under the typical 215
With a total market value of 0 EUR, Bayer has with a one year low of 0.03EUR and a one year high of 0.04EUR .
More About Bayer (ETR:BAYN)
Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, adhesives and sealants; and selected chemical intermediates.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.